Meeting report: "Human endogenous retroviruses: HERVs or transposable elements in autoimmune, chronic inflammatory and degenerative diseases or cancer", Lyon, France, november 5th and 6th 2019 - an MS scientist's digest

David Kremer; Vivien Weyers; Joel Gruchot; Peter Göttle; Hans-Peter Hartung; Hervé Perron; Patrick Küry

doi:10.1016/j.msard.2020.102068

Meeting report: "Human endogenous retroviruses: HERVs or transposable elements in autoimmune, chronic inflammatory and degenerative diseases or cancer", Lyon, France, november 5th and 6th 2019 - an MS scientist's digest

Mult Scler Relat Disord. 2020 Jul:42:102068. doi: 10.1016/j.msard.2020.102068. Epub 2020 Apr 8.

Authors

David Kremer¹, Vivien Weyers², Joel Gruchot², Peter Göttle², Hans-Peter Hartung², Hervé Perron³, Patrick Küry²

Affiliations

¹ Department of Neurology, Medical Faculty, Heinrich-Heine-University, 40225 Düsseldorf, Germany. Electronic address: [email protected].
² Department of Neurology, Medical Faculty, Heinrich-Heine-University, 40225 Düsseldorf, Germany.
³ GeNeuro, CH-1228 Geneva, Switzerland.

PMID: 32302965
DOI: 10.1016/j.msard.2020.102068

Abstract

The Third International Workshop on Human Endogenous Retroviruses and disease (www.hervanddisease.com), addressing HERVs or transposable elements in autoimmune, chronic inflammatory and degenerative diseases or cancer, in Lyon, France on November 5-6th 2019, once again gathered an international group of basic and clinical scientists investigating the involvement of human endogenous retroviruses (HERVs) in human diseases.

Keywords: Human endogenous retroviruses; Multiple sclerosis; Neuroprotection; Temelimab; pHERV-W ENV.

MeSH terms

Antibodies, Monoclonal, Humanized / pharmacology*
Congresses as Topic*
Endogenous Retroviruses*
France
Humans
Immunologic Factors / pharmacology*
Multiple Sclerosis* / drug therapy
Multiple Sclerosis* / etiology
Multiple Sclerosis* / virology

Substances

Antibodies, Monoclonal, Humanized
Immunologic Factors
temelimab